Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk

Dow Jones

2025/08/15

1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. "We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy," Clammer says. "The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite." Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels "the obligation to lead a company that truly makes the world a safer place every day." Shares rise 9.9% to $15.37. (dean.seal@wsj.com)

(END) Dow Jones Newswires

August 14, 2025 15:31 ET (19:31 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559969733"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559969733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559969733?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559969733","market":"hk","top_or_hot":-1,"title":"Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1531 ET - <a href=\"https://laohu8.com/S/CLBT\">Cellebrite</a>'s newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 15:31 ET (19:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellebrite's New Chief Beat Cancer a Month Before Joining C-Suite -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-15 03:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1531 ET - <a href=\"https://laohu8.com/S/CLBT\">Cellebrite</a>'s newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 15:31 ET (19:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2559969733","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559969733","pubTimestamp":1755199860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK4613":"AI应用软件","CLBT":"Cellebrite"},"translate_title":"Cellebrite新任首席执行官在加入最高管理层前一个月战胜了癌症——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLBT":1},"content_text":"1531 ET - Cellebrite's newly permanent chief executive, Thomas Hogan, took over the role on an interim basis in January, about a month after completing final treatments for Stage 4 non-Hodgkin's lymphoma. Hogan is in complete remission and has steadily regained his energy and stamina, Chairman Adam Clammer says on a call with analysts. Hogan had been the board's executive chairman since 2023 until his interim CEO appointment. \"We were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy,\" Clammer says. \"The board is unanimous in its conviction that Tom is the right individual to lead Cellebrite.\" Hogan says on the analyst call that he wouldn't have returned to work for any company other than Cellebrite, where he feels \"the obligation to lead a company that truly makes the world a safer place every day.\" Shares rise 9.9% to $15.37. (dean.seal@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 15:31 ET (19:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}